283 related articles for article (PubMed ID: 36238550)
21. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
22. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
[TBL] [Abstract][Full Text] [Related]
23. Mercaptopurine induced myelosuppression in a child with a
Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacogenomics of thiopurine S-methyltransferase.
Zhou S
Curr Clin Pharmacol; 2006 Jan; 1(1):119-28. PubMed ID: 18666383
[TBL] [Abstract][Full Text] [Related]
25. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Abaji R; Krajinovic M
Pharmgenomics Pers Med; 2017; 10():143-156. PubMed ID: 28507448
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
[TBL] [Abstract][Full Text] [Related]
28. Reducing risk in thiopurine therapy.
Marinaki AM; Arenas-Hernandez M
Xenobiotica; 2020 Jan; 50(1):101-109. PubMed ID: 31682552
[TBL] [Abstract][Full Text] [Related]
29. [Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
Tárnok A
Orv Hetil; 2019 Feb; 160(5):179-185. PubMed ID: 30686035
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of thiopurines.
Franca R; Zudeh G; Pagarin S; Rabusin M; Lucafò M; Stocco G; Decorti G
Cancer Drug Resist; 2019; 2(2):256-270. PubMed ID: 35582727
[TBL] [Abstract][Full Text] [Related]
32. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
33. Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients.
Park Y; Kim H; Choi JY; Yun S; Min BJ; Seo ME; Im HJ; Kang HJ; Kim JH
Front Pharmacol; 2019; 10():654. PubMed ID: 31244663
[No Abstract] [Full Text] [Related]
34. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
35. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
[TBL] [Abstract][Full Text] [Related]
36. Comparison of three methods for measuring thiopurine methyltransferase activity in red blood cells and human leukemia cells.
Karim H; Appell ML; Fotoohi A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():80-5. PubMed ID: 24113235
[TBL] [Abstract][Full Text] [Related]
37. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
[TBL] [Abstract][Full Text] [Related]
38. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
39. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease.
Deben DS; Wong DR; van Bodegraven AA
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1433-1444. PubMed ID: 35023443
[TBL] [Abstract][Full Text] [Related]
40. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
